Regeneron Pharmaceuticals (($REGN)) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals is spearheading a study titled ...

REGN stock fell 25.8% from a high of $738.84 on 8 April 2022 to $548.35 on 14 June 2022, vs. a peak-to-trough decline of 25.4% for the S&P 500 The stock fully recovered to its pre-Crisis peak by 4 ...

Regeneron Pharmaceuticals (NASDAQ:REGN) shares witnessed a notable 19% decline on Friday, May 30, in the wake of the unexpected failure of itepekimab, its chronic obstructive pulmonary disease ...

This 120% rise for Regeneron stock since late 2019 can primarily be attributed to 1.the company’s P/S ratio rising 50% to 12.6x revenues vs. 8.4x in 2019, 2. Regeneron’s revenue growth of 44% ...

Shares of Regeneron Pharmaceuticals, Inc.REGN have dropped 35.6% in the past six months compared with the industry’s decline of 12.3%.. The stock has underperformed the sector and the S&P 500 ...

Regeneron Pharmaceuticals stock surged on strong Q2 results and pipeline developments. Read this article to know if REGN can deliver more growth.

Regeneron just posted another impressive quarter for earnings (+16% YoY) and revenues (+17% YoY). Growth is set to slow after a one-time boost from its COVID antibody cocktail last year and an ...

This was the stock's second consecutive day of losses.

Regeneron isn't concerned, as the decision wasn't a result of any issues relating to the drug's safety or efficacy. Investor Alert: Our 10 best stocks to buy right now › NASDAQ: REGN ...

Regeneron Pharmaceuticals (Nasdaq:REGN) has been upgraded by TheStreet Ratings from a hold to buy.

The stock's fall snapped a two-day winning streak.